Come up with a name for your new list and we'll add to it:
Symphogen raised a round of funding on January 19, 2007. Investors include
Gilde Healthcare Partners.
Symphogen is developing next-generation antibody therapeutics for the treatment of cancer and is dedicated to bringing truly innovative oncology products to the market. The company has advanced the fr…